No material discrete corporate events or announcements were identified for AbbVie Inc. in recent reporting cycles. Successive briefings dated 2026-06-01, 2026-06-09, and 2026-06-17 each noted the absence of new corporate disclosures, with AbbVie's trailing twelve-month revenue through 31 March 2026 serving as the primary data anchor across all three cycles [Brief - 2026-06-17] [Brief - 2026-06-09] [Brief - 2026-06-01]. No product approvals, litigation settlements, or management changes were recorded in the available briefing data during this period.
As of 31 March 2026, AbbVie reported trailing twelve-month revenue of $62.82 billion, representing year-over-year growth of 12.43%. Gross margin stood at 67.37% and operating margin at 24.41%, while net margin was 5.79% on net income of $3.64 billion. EPS declined 45.83% year-over-year. The company held $9.39 billion in cash against total debt of $64.50 billion. The reported P/E ratio was 115.71 [SEC 10-Q - ABBV - 2026-03-31].
Institutional ownership changes in the most recent 13F reporting period were material across several large filers. Millennium Management added 61% to its existing ABBV position, and Bridgewater Associates increased its position by 114% [SEC 13F - Millennium - Q1 2026] [SEC 13F - Bridgewater - Q1 2026]. Conversely, Citadel reduced its position by 11% and AQR Capital reduced its holding by 23% [SEC 13F - Citadel - Q1 2026] [SEC 13F - AQR Capital - Q1 2026]. These divergent moves across major institutional filers constitute the primary trigger for this report.
The prevailing macro environment shows the 10-year US Treasury yield at 4.50% and the 2-year yield at 4.16%, producing a normal yield curve spread of 34 basis points [FRED DGS10] [FRED DGS2]. A positive term spread of this magnitude reflects a standard relationship between short- and long-duration sovereign rates within the current interest rate environment.